Search clinical trials for: p97 Inhibitor CB-5339 Tosylate

Total 1386 results

National Cancer Institute (NCI)

Withdrawn

Testing the Safety of CB-5339 in Patients With Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
Cleave Therapeutics, Inc.

Completed

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myeloid Leukemia, in Relapse

United States, Australia
Cetylite Industries

Completed

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

Anesthesia

United States
Cetylite Industries

Completed

Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers

No Disease State or Condition

United States
Calithera Biosciences, Inc

Completed

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Acute Myeloid Leukemia (AML) | Acute Lymphocytic Leukemia (ALL)

United States
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Renal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Leptomeningeal Neoplasm | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Childhood Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Tallikut Pharmaceuticals, Inc.

Completed

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

Atherosclerosis

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2

United States
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
University of Alabama at Birmingham

Terminated

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (BRCA)

Ovarian Cancer | Resistant BRCA Wild-Type Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Glenn J. Hanna
Adenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AG

Recruiting

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
Massachusetts General Hospital
Pfizer; Prostate Cancer Foundation; Calithera Biosciences, Inc

Not yet recruiting

Telaglenastat + Talazoparib In Prostate Cancer

Prostate Cancer Metastatic

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell...

United States
Yonsei University

Unknown

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

Lung Cancer

Korea, Republic of
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Multiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHL

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Recurrent Thyroid Cancer | Anaplastic Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Uterine Carcinosarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma

United States, Canada
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Uterine Carcinosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Uterine Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage IV Uterine Sarcoma | Adult Angiosarcoma | Adult Epithelioid Sarcoma | Adult Leiomyosarcoma | Adult Synovial Sarcoma and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Chronic Myeloid Leukemia

China
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Recurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...

Canada
National Cancer Institute (NCI)

Completed

S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder | Adenocarcinoma of the Gallbladder | Adenocarcinoma With... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant

Advanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Advanced Malignant Neoplasm

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States

Search clinical trials for: p97 Inhibitor CB-5339 Tosylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations